See today's BioWorld
To read the full story, subscribe or sign in.

Back to work: FDA finds deficiencies in Provention’s BLA for diabetes

April 9, 2021
By Lee Landenberger
The FDA told Provention Bio Inc. that its BLA under priority review for teplizumab needs some work but the May 27 advisory committee meeting to discuss the application in full is still on the calendar.
BioWorld Regulatory Diabetes FDA